Dradi C, Riceputi G, Biagioli R, Riva P
Minerva Med. 1979 Jan 14;70(2):135-41.
The indications for radioisotope management in Basedow's disease and the complications involved are explained. Particular reference is made to the possibility of early or late hypothyroidism when 131I and 125I are employed for this purpose. The physiopathogenetic bases for this are examined in relation to dosage and early diagnosis. Results obtained with small doses (fractionated in some cases) of these isotopes in 126 patients with thyrotoxicosis. One-year and later follow-up was directed to the clinical and functional responses to treatment in the light of age, sex, T4, maximum uptake, eff. T/2, thyroid size, and doses administered. Recurrences were rather frequent and further doses were given. However, early hypothyroidism was very rare. This appeared to be related to the dose administered and inversely to gland size. The results are compared with those in the literature.
本文解释了放射性同位素在格雷夫斯病中的管理指征以及相关并发症。特别提到了使用¹³¹I和¹²⁵I治疗时出现早期或晚期甲状腺功能减退的可能性。结合剂量和早期诊断对其生理病理基础进行了研究。观察了126例甲状腺毒症患者使用小剂量（某些情况下为分次给药）这些同位素的治疗结果。根据年龄、性别、T4、最大摄取量、有效半衰期、甲状腺大小和给药剂量，对治疗的临床和功能反应进行了为期一年及以后的随访。复发情况较为常见，因此给予了进一步的剂量。然而，早期甲状腺功能减退非常罕见。这似乎与给药剂量有关，与腺体大小成反比。将结果与文献中的结果进行了比较。
